课题基金 / 基金详情

OSTEOPOROSIS

OSTEOPOROSIS
骨质疏松症
批准号：
6265518
负责人：
NORMAN L BELL
金额：
$1.74万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265518
关键词：
alendronate bone density bone metabolism clinical research drug adverse effect drug screening /evaluation human subject human therapy evaluation male osteoporosis skeletal disorder chemotherapy

项目摘要

项目成果

NORMAN L BELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To assess the treatment effect of oral alendronate 10 mg/day versus placebo on the change in BMD of the spine when administered for up to 24 months in men with osteoporosis. To define the safety/tolerability profile of oral alendronate when administered in men with osteoporosis. To assess the treatment effects of alendronate 10 mg/day versus placebo on the change in hip and total body BMD when administered for 24 months in men with osteoporosis. To examine the effects of alendronate 10 mg/day on biochemical markers of bone turnover (urinary N-telopeptide crosslinks and serum bone-specific alkaline phosphatase) in men with osteoporosis. To examine the relationship between the changes in bone mass at the spine and baseline: (a) BMD, (b) biochemical markers of bone turnover (c) gonadal status (d) age (e) geographic location (U.S. vs non-U.S.) (f) renal function (g) height.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TESTOSTERONE DEFICIENCY & BONE LOSS
POSTMENOPAUSAL OSTEOPOROSIS
POSTMENOPAUSAL OSTEOPOROSIS
POSTMENOPAUSAL OSTEOPOROSIS
海外基金